Kilambi News
Tuesday, November 17, 2026

Life sciences also notable: Sofinnova crossover fund, Apple health study app

Life Sciences Monday, November 16, 2026 - Updated Nov 16, 2026 07:09

Sofinnova closed its second crossover fund at 725 million euros, Apple and OpenEvidence launched an experimental health chat app, and the MHRA published its Women's Health Programme for 2026 to 2030.

Why it matters: Financing and product items below the Seawolf launch that leads the beat today.

Data as of Endpoints News and BioPharma Dive reporting of November 16, 2026; MHRA corporate report of November 16, 2026; Apple item from STAT and TechCrunch reporting of November 16, 2026 in the feed pool.

Sofinnova closes 725 million euro crossover fund. Sofinnova Partners has closed its second crossover fund at 725 million euros for late stage European biotech companies, Endpoints News and BioPharma Dive reported. The fund gives the Paris firm dedicated capital for the crossover rounds that carry private European drug developers into public markets, a segment where European supply has been thin.

Apple and OpenEvidence launch health chat study. Apple and OpenEvidence have launched an experimental health chat app, reported by STAT and TechCrunch, with Apple framing it as a study of how people use AI for health questions. The launch puts a consumer health chatbot from the largest device maker into direct comparison with the clinical tools already in use.

MHRA publishes Women’s Health Programme. The UK Medicines and Healthcare products Regulatory Agency published its Women’s Health Programme for 2026 to 2030 as a corporate report. The programme sets the regulator’s priorities for women’s health products over the next four years.

Sources

  1. Sofinnova closes second crossover fund at €725M for late-stage European biotechs - Endpoints News - 2026-11-16
  2. One of Europe's leading VCs banks a €725M 'crossover' fund - BioPharma Dive - 2026-11-16
  3. Corporate report: MHRA Women's Health Programme 2026-2030 - MHRA - 2026-11-16